| Статус: | Unknown status |
| Фаза: | Phase 3 |
| Начало: | 1 декабря 2013 г. |
| Окончание: | 1 апреля 2021 г. |
| Описание: | - To evaluate the efficacy of bendamustine in combination with rituximab as first line in patients with follicular lymphoma, 1-3A cytological type. - To evaluate the safety, tolerability and feasibility of bendamustine in combination with rituximab as 1st line in patients with follicular lymphoma, 1-3A cytological type. - To evaluate the impact of the regimen modification (bendamustine dose modification and/or extension of inter-cycle interval) into duration of complete and partial responses. - To evaluate estimated treatment duration, reasons of treatment withdrawal. - To evaluate the possibility of unification and standardization of therapy protocol BR (rituximab 375 mg/m2 on day 1 and bendamustine 90 mg/m2 on days 1-2). - To evaluate factors affecting overall and progression-free survival. |
| смотреть на ClinicalTrials.gov |
| Статус: | Unknown status |
| Фаза: | Phase 3 |
| Начало: | 1 декабря 2013 г. |
| Окончание: | 1 апреля 2021 г. |
| Описание: | - To evaluate the efficacy of bendamustine in combination with rituximab as first line in patients with follicular lymphoma, 1-3A cytological type. - To evaluate the safety, tolerability and feasibility of bendamustine in combination with rituximab as 1st line in patients with follicular lymphoma, 1-3A cytological type. - To evaluate the impact of the regimen modification (bendamustine dose modification and/or extension of inter-cycle interval) into duration of complete and partial responses. - To evaluate estimated treatment duration, reasons of treatment withdrawal. - To evaluate the possibility of unification and standardization of therapy protocol BR (rituximab 375 mg/m2 on day 1 and bendamustine 90 mg/m2 on days 1-2). - To evaluate factors affecting overall and progression-free survival. |
| смотреть на ClinicalTrials.gov |